Seema S. Deshpande
Emory University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Seema S. Deshpande.
Transfusion | 2006
Jeanne E. Hendrickson; Maxime Desmarets; Seema S. Deshpande; Traci E. Chadwick; Christopher D. Hillyer; John D. Roback; James C. Zimring
BACKGROUND: Most alloantigens on transfused red blood cells (RBCs) are weakly immunogenic, with only a 2 to 6 percent overall immunization rate even in patients receiving multiple transfusions. Although recipient genetics may contribute to responder and/or nonresponder status, in most cases HLA type does not predict humoral response to RBC antigens. In contrast, rates of alloimmunization do correspond to the underlying disease status of transfusion recipients, suggesting that acquired host factors may play an important role. In this context, it was hypothesized that the inflammatory status of a transfusion recipient would influence immunization to transfused RBCs.
Oncogene | 2004
J. Gregory Powell; Xiying Wang; Brandon L. Allard; Mustafa Sahin; Xiao Li Wang; Ian D. Hay; Henry J. Hiddinga; Seema S. Deshpande; Todd G. Kroll; Stefan K. Grebe; Norman L. Eberhardt; Bryan McIver
Follicular thyroid carcinoma (FTC) frequently harbors the PAX8/PPARγ fusion gene (PPFP); however, its oncogenic role and mechanism(s) of action remain undefined. We investigated PPFPs effects on cell growth, apoptosis, cell–cell, and cell–matrix interactions in immortalized human thyroid cells (Nthy-ori 3-1) and NIH 3T3 cells. PPFP expression increased the growth of transient and stable Nthy-ori transfectants (∼threefold by 72 h). There was an 8.4% increase of cells in the S+G2/M phase, a 7.8% decrease in cells in the G0+G1 phase and a 66% decline in apoptosis at 72 h. Stable Nthy-ori PPFP transfectants grew in soft agar, and PPFP-transfected NIH 3T3 cells exhibited efficient focus formation, suggesting loss of anchorage-dependent growth and contact inhibition, respectively. Overexpression of PPARγ in Nthy-ori cells did not recapitulate PPFPs growth effects. Treatment of Nthy-ori cells with an irreversible PPARγ inhibitor mimicked the growth-promoting effects of PPFP and co-expression of PPFP and PPARγ blocked PPARγ transactivation activity. Our data provide functional evidence that PPFP acts as an oncoprotein, whose transforming properties depend in part on inhibition of PPARγ. Our data suggest that PPFP contributes to malignant transformation during FTC oncogenesis by acting on several cellular pathways, at least some of which are normally regulated by PPARγ.
Cancer Research | 2008
Weng-Onn Lui; Lingchun Zeng; Victoria Rehrmann; Seema S. Deshpande; Maria Tretiakova; Edwin L. Kaplan; Ingo B. Leibiger; Barbara Leibiger; Ulla Enberg; Anders Höög; Catharina Larsson; Todd G. Kroll
The discovery of gene fusion mutations, particularly in leukemia, has consistently identified new cancer pathways and led to molecular diagnostic assays and molecular-targeted chemotherapies for cancer patients. Here, we report our discovery of a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a family of somatic PPARgamma fusion mutations exist in thyroid cancer. The CREB3L2-PPARgamma fusion encodes a CREB3L2-PPARgamma fusion protein that is composed of the transactivation domain of CREB3L2 and all functional domains of PPARgamma1. CREB3L2-PPARgamma was detected in <3% of thyroid follicular carcinomas. Engineered overexpression of CREB3L2-PPARgamma induced proliferation by 40% to 45% in primary human thyroid cells, consistent with a dominant oncogenic mechanism. Wild-type CREB3L2 was expressed in the thyroid as a bZIP transcription factor with a transmembrane domain that has flanking S1P and S2P proteolytic cleavage sites. Native CREB3L2 was cleaved to nuclear CREB3L2 by regulated intramembrane proteolysis in normal thyroid cells that expressed the S1P and S2P proteases. Nuclear CREB3L2 stimulated transcription 8-fold from the EVX1 cyclic AMP (cAMP) response element in the absence of cAMP, whereas CREB3L2-PPARgamma inhibited transcription 6-fold from EVX1 in the same experiments. CREB3L2-PPARgamma also inhibited 4-fold the expression of thyroglobulin, a native cAMP-responsive gene, in primary thyroid cells treated with thyroid-stimulating hormone. Our findings identify a novel CREB3L2-PPARgamma gene fusion mutation in thyroid carcinoma and reveal a thyroid signaling pathway that is regulated by intramembrane proteolysis and disrupted in cancer.
Biochemical Society Transactions | 1992
Keith D. Wilkinson; Seema S. Deshpande; Christopher N. Larsen
Biochemistry | 2000
Luming Yin; Bryan A. Krantz; Nathaniel S. Russell; Seema S. Deshpande; Keith D. Wilkinson
Blood | 2005
James C. Zimring; Gregory A. Hair; Traci E. Chadwick; Seema S. Deshpande; Kimberly M. Anderson; Christopher D. Hillyer; John D. Roback
Blood | 2006
James C. Zimring; Gregory A. Hair; Seema S. Deshpande; John Horan
Blood | 2006
Tom E. Howard; Kevin R. Viel; Karl Fernstrom; Seema S. Deshpande; Afshin Ameri; M. Showkat Ali; Cynthia Channell; Rathi V. Iyer; Raymond G. Watts; Charles L. Lutcher; Shelley Nakaya; Carol K. Kasper; Arthur R. Thompson; Thomas C. Abshire; Laura Almasy
Blood | 2005
James C. Zimring; Gregory A. Hair; Traci E. Chadwick; Seema S. Deshpande; Kimberly M. Anderson; Christopher D. Hillyer; John D. Roback
Blood | 2005
James C. Zimring; Gregory A. Hair; Seema S. Deshpande; John Horan